Pretreatment serum soluble interleukin-2 receptor level predicts survival in patients with newly diagnosed follicular lymphoma

Abstract

This retrospective, multicenter observational study investigated the prognostic value of pretreatment serum soluble interleukin-2 receptor (sIL-2R) level for outcomes of newly diagnosed follicular lymphoma (FL) grade 1-3a who required treatment at diagnosis. A total of 628 patients were recorded, and 502 of these were eligible for analysis. Patients were divided into four quartiles, based on their serum sIL-2R levels as follows: Q1 (sIL-2R < 520 IU/mL), Q2 (520 ≤ sIL-2R < 1030 IU/mL), Q3 (1030 ≤ sIL-2R < 2530 IU/mL) and Q4 (sIL-2R ≥ 2530 IU/mL). Using a multivariable Cox proportional-hazards model, we showed the adjusted probability of overall survival (OS) decreased with increasing serum sIL-2R levels (p for trend = .007). Similar trends were observed for disease-specific survival (DSS) and progression-free survival (PFS). In conclusion, pretreatment serum sIL-2R levels significantly and dose-dependently associate with worse outcomes (OS, DSS and PFS) of patients with newly diagnosed FL.

Keywords:

• Soluble-interleukin-2 receptor
• follicular lymphoma
• prognosis

Acknowledgements

The authors would like to thank all members of this study for their contribution. The authors also thank their colleagues from Osaka University Center of Medical Data Science and Advanced Clinical Epidemiology Investigator’s Research Project for providing valuable insight and expertise for their research.

Disclosure statement

Kenji Nozaki reports personal fees from Chugai and Celgene, outside the submitted work.

Satoru Kosugi reports personal fees from Novartis, Bristol-Myers Squibb, Eisai, Takeda, Kyowa Kirin, Chugai, Ono, Nippon Shinyaku, Janssen, Celgene and Pfizer, outside the submitted work.

Hirohiko Shibayama reports grants and personal fees from Eisai, during the conduct of the study; grants and personal fees from Takeda, Ono, Sumitomo Dainippon Pharma, Mundi Pharma and Nippon Shinyaku; grants from Teijin, MSD, Shionogi and Taiho; personal fees from Novartis, Janssen, Celgene, Chugai, Kyowa Kirin, Otsuka, AstraZeneca, Avvie, Daiichi Sankyo, Fujimoto, Sanofi, Bristol-Meyers Squibb and Pfizer, outside the submitted work.

Author contributions

Conception and design: Kenji Nozaki and Hirohiko Shibayama. Provision of study materials and patients: all authors. Collection and assembly of data: Kenji Nozaki, Hiroyuki Sugahara, Shuji Ueda, Jun Ishikawa, Shigeo Fuji, Hiroaki Masaie, Yuma Tada, Takahiro Karasuno, Masato Iida, Hideki Mitsui, Tsuyoshi Kamae, Norimitsu Saito, Yasuhiro Moriyama, Manabu Kawakami, Ruri Kato, Yoshiki Nakae, Toru Kida, Satoru Kosugi, Masashi Nakagawa, Yozo Uchida, Yasuhiko Azenishi and Hirohiko Shibayama. Data analysis and interpretation: Kenji Nozaki, Ryouto Sakaniwa and Tetsuhisa Kitamura. Manuscript writing: Kenji Nozaki. Final approval of manuscript: all authors.

Additional information

Funding

The study group has received research funding from Eisai Co.